Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7258   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-003571-17
    Sponsor's Protocol Code Number:CY6022
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-07-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-003571-17
    A.3Full title of the trial
    An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction.
    Estudio sin enmascaramiento de CK­3773274 en pacientes con miocardiopatía hipertrófica (MH) sintomática y obstrucción del infundíbulo del ventrículo izquierdo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    This study is being performed to collect long-term safety and tolerability data of CK-3773274 on patients with obstructive hypertrophic cardiomyopathy (oHCM).
    Este estudio se está realizando para recopilar datos de seguridad y tolerabilidad a largo plazo de CK-3773274 en pacientes con miocardiopatía hipertrófica obstructiva (MCO).
    A.4.1Sponsor's protocol code numberCY6022
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCytokinetics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCytokinetics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCytokinetics Inc
    B.5.2Functional name of contact pointMedical Affairs
    B.5.3 Address:
    B.5.3.1Street Address280 East Grand Avenue
    B.5.3.2Town/ citySouth San Francisco CA
    B.5.3.3Post code94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number16506242929
    B.5.6E-mailmedicalaffairs@cytokinetics.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code CK-3773274
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCK-3773274
    D.3.9.2Current sponsor codeCK-3773274
    D.3.9.3Other descriptive name(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
    D.3.9.4EV Substance CodeSUB197451
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code CK-3773274
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCK-3773274
    D.3.9.2Current sponsor codeCK-3773274
    D.3.9.3Other descriptive name(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
    D.3.9.4EV Substance CodeSUB197451
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    obstructive hypertrophic cardiomyopathy (oHCM)
    miocardiopatía hipertrófica obstructiva (MHO)
    E.1.1.1Medical condition in easily understood language
    heart disease with thickening of the heart muscle
    Cardiopatía con engrosamiento del miocardio.
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10020871
    E.1.2Term Hypertrophic cardiomyopathy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the safety and tolerability of CK-3773274 in patients with symptomatic oHCM
    Determinar la seguridad y la tolerabilidad de CK­3773274 en pacientes con MHO sintomática
    E.2.2Secondary objectives of the trial
    To assess long-term effects of CK-3773274 on left ventricular outflow tract gradient (LVOT-G)

    To assess steady-state PK during long-term administration of CK-3773274
    Evaluar los efectos a largo plazo de CK­3773274 en el gradiente del infundíbulo del ventrículo izquierdo (G-IVI)
    Evaluar la FC en estado de equilibrio durante la administración a largo plazo de CK­3773274 CK­3773274
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    A cardiac magnetic resonance (CMR) imaging sub-study will assess the effects of long-term administration of CK-3773274 dosing on cardiac morphology, function and fibrosis in those oHCM patients who are eligible and elect to participate. CMR will be performed at baseline.
    Patients with eGFR <30 mL/min/1.73 m2 or an allergy to gadolinium may only be given non-contrast CMR.
    Subsequent CMR studies will be performed at the Q12W visit corresponding to Weeks 48, 144 and 240.
    Un subestudio de imágenes de resonancia magnética cardíaca (RMC) evaluará los efectos de la administración a largo plazo de CK-3773274 sobre la morfología cardíaca, la función y la fibrosis en los pacientes con MHo que sean elegidos para participar en el estudio y cumplan los criterios pertinentes. Se realizará una RMC en el periodo inicial.
    En el caso de los pacientes con una TFGe <30 ml/min/1,73 m2 o alergia al gadolinio, es posible que solo se realice una RMC sin contraste. Los estudios de RMC posteriores se realizarán en las visitas programadas cada 12 semanas correspondientes a las semanas 48, 144 y 240.
    E.3Principal inclusion criteria
    Patients are eligible to be included in the study only if all the following criteria apply:
    1. Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions for the duration specified in the Schedule of Activities.

    2. Completion of a Cytokinetics trial investigating CK-3773274. If unable to complete due to circumstances not related to compliance or safety, Medical Monitor may review and determine eligibility.

    3. Left ventricular ejection fraction ≥ 55%.

    4. Male patients are eligible to participate if they agree to the following during the study and for at least 10 weeks after the last dose of IP:
    a. Refrain from donating sperm
    Plus either:
    b. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
    OR
    Must agree to use a male condom and, when his female partner is a woman of childbearing potential, have his female partner use a highly effective method of contraception (as described in Appendix 3 [Section 10.3] of the protocol)

    5. A female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
    a. Is not a woman of childbearing potential (WOCBP; as described in Appendix 3 [Section 10.3] of the protocol)
    OR
    Is a WOCBP and using a highly effective method of contraceptive (as described in Appendix 3 [Section 10.3]) during the study and for at least 4 weeks after the last dose of IP.
    b. A WOCBP must have a negative pregnancy test (urine or serum as required by local regulations) within 3 days before the first dose of study intervention.
    Note: The Principal Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    Contraceptive use by men or WOCBPs should be consistent with the guidance in Appendix 3 (Section 10.3) and local regulations regarding the methods of contraception for those participating in clinical studies.

    6. Willing and able to complete all screening procedures.
    En el estudio solo podrán participar los pacientes que cumplan todos los criterios enumerados a continuación:
    1. Pacientes con capacidad de comprensión y que estén dispuestos a firmar un FCI y a cumplir todas las restricciones y procedimientos del estudio durante el intervalo de tiempo especificado en el calendario de actividades.
    2. Finalización de un ensayo de Cytokinetics en el que se investigue CK-3773274. En caso de que no se pueda finalizar el ensayo debido a circunstancias no relacionadas con el cumplimiento o la seguridad, el supervisor médico podrá revisar y determinar la elegibilidad.
    3. Fracción de eyección ventricular izquierda ≥55 %.
    4. Los pacientes varones podrán participar si aceptan cumplir con lo siguiente a lo largo del estudio y durante como mínimo las diez semanas posteriores a haber recibido la última dosis del PEI:
    a. Abstenerse de donar semen.
    Más una de las siguientes:
    b. Abstenerse de tener relaciones heterosexuales de acuerdo con su estilo de vida preferido y habitual (abstinencia a largo plazo y de forma persistente) y aceptar mantener dicha abstinencia;
    O BIEN,
    comprometerse a usar un preservativo masculino y, en caso de que su pareja femenina sea una mujer potencialmente fértil, pedir a su pareja femenina que use un método anticonceptivo muy eficaz (tal y como se describe en el Apéndice 3 [Apartado 10.3] del protocolo).
    5. Una paciente femenina podrá participar si no está embarazada ni en fase de lactancia, y además cumple una de las siguientes condiciones:
    a. No ser una mujer potencialmente fértil (MPF, tal y como se describe en el Apéndice 3 [Apartado 10.3] del protocolo);
    O BIEN,
    ser una MPF y usar un método anticonceptivo muy eficaz (tal y como se describe en el Apéndice 3 [Apartado 10.3]) durante el estudio y, como mínimo, durante las cuatro semanas siguientes a haber recibido la última dosis del PEI.
    b. Las MPF deben obtener un resultado negativo en una prueba de embarazo (orina o suero según lo requiera la normativa local) en el plazo de los tres días anteriores a recibir la primera dosis de la intervención del estudio.
    Nota: El investigador principal tendrá la responsabilidad de revisar los antecedentes médicos, el historial menstrual y la actividad sexual reciente para reducir el riesgo de incluir a una mujer con un embarazo precoz no detectado.
    El uso de anticonceptivos por parte de los hombres y las MPF debe ser conforme con las pautas del Apéndice 3 (Apartado 10.3) y la normativa local relativa a los métodos anticonceptivos en participantes en estudios clínicos.
    6. Pacientes dispuestos a completar todos los procedimientos de selección.
    E.4Principal exclusion criteria
    • Has taken any investigational study drug other than CK-3773274 within 30 days prior to screening.

    • Since completion of a previous trial of CK-3773274 has:
    − Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days.

    − Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).

    • Has current obstructive coronary artery disease (>70% stenosis documented in one or more arteries).

    • Has moderate or severe aortic valve stenosis.

    • Had a confirmed LVEF <40% with an associated dose interruption during CY 6021. If data from the participant's cohort has been unblinded, the patient may be considered for entry into CY 6022 (see Section 6.6.1 of the protocol).

    • Has been treated with drugs that have negative inotropic activity within 30 days prior to screening.

    • History of syncope or sustained ventricular tachyarrhythmia with exercise within 30 days prior to screening.

    • History of appropriate ICD shock within 30 days prior to screening.

    • Has received treatment with mavacamten within 3 months prior to screening.


    Exclusion Criteria for CMR sub-study:
    • Inability to tolerate CMR.

    • Has an implantable cardioverter-defibrillator (ICD).

    • Has a cardiac pacemaker.
    •Has taken any investigational study drug other than CK­3773274 within 30 days prior to screening.
    •Since completion of a previous trial of CK­3773274 has:
    Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days.
    Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).
    •Has current obstructive coronary artery disease (>70% stenosis documented in one or more arteries)
    •Has moderate or severe aortic valve stenosis
    •Had a confirmed LVEF <40% with an associated dose interruption during CY 6021. If data from the participant's cohort has been unblinded, the patient may be considered for entry into CY 6022 (see Section 6.6.1).
    •Has been treated with drugs that have negative inotropic activity within 30 days prior to screening.
    •History of syncope or sustained ventricular tachyarrhythmia with exercise within 30 days prior to screening.
    •History of appropriate ICD shock within 30 days prior to screening.
    •Has received treatment with mavacamten within 3 months prior to screening.
    Exclusion Criteria for CMR sub-study
    •Inability to tolerate CMR
    •Has an implantable cardioverter-defibrillator (ICD)
    •Has a cardiac pacemaker
    E.5 End points
    E.5.1Primary end point(s)
    • Patient incidence of reported adverse events (AEs)

    • Patient incidence of reported serious adverse events (SAEs)

    • Patient incidence of left ventricular ejection fraction (LVEF) <50%
    • Incidencia en los pacientes de los acontecimientos adversos (AA) notificados
    • Incidencia en los pacientes de los acontecimientos adversos graves (AAG) notificados
    • Incidencia en los pacientes de una fracción de expulsión del ventrículo izquierdo (FEVI) <50 %
    E.5.1.1Timepoint(s) of evaluation of this end point
    End of participation
    Fin de participación
    E.5.2Secondary end point(s)
    1. Change from baseline values at 12-week intervals through end of participation in:
    − Peak LVOT-G at rest and with Valsalva provocation

    − Proportion of patients with resting LVOT-G <50 mmHg

    − Proportion of patients with resting LVOT-G <30 mmHg

    − Proportion of patients with post-Valsalva LVOT-G <50 mmHg

    − Proportion of patients with post-Valsalva LVOT-G <30 mmHg

    − Proportion of patients with LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg

    2. Time to the following event through last follow-up
    − First resting LVOT-G <50 mmHg

    − First resting LVOT-G <30 mmHg
    − First post-Valsalva LVOT-G <50 mmHg

    − First post-Valsalva LVOT-G <30 mmHg

    − First LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg

    3. C^trough at 12-week intervals through end of participation
    1. Cambio desde los valores basales, a intervalos de 12 semanas y hasta el final de la participación, de:
     Valor máximo del G-IVI en reposo y con provocación de Valsalva
     Proporción de pacientes con G-IVI <50 mmHg en reposo
     Proporción de pacientes con G-IVI <30 mmHg en reposo
     Proporción de pacientes con G-IVI <50 mmHg tras la maniobra de Valsalva
     Proporción de pacientes con G-IVI <30 mmHg tras la maniobra de Valsalva
     Proporción de pacientes con FEVI ≥50 %, G-IVI <30 mmHg en reposo y G-IVI <50 mmHg tras la maniobra de Valsalva
    2. Tiempo transcurrido hasta el siguiente acontecimiento desde el último seguimiento
     Primer G-IVI <50 mmHg en reposo
     Primer G-IVI <30 mmHg en reposo
     Primer G-IVI <50 mmHg tras la maniobra de Valsalva
     Primer G-IVI <30 mmHg tras la maniobra de Valsalva
     Primer FEVI ≥50 %, G-IVI <30 mmHg en reposo y G-IVI <50 mmHg tras la maniobra de Valsalva
    E.5.2.1Timepoint(s) of evaluation of this end point
    End of participation
    Fin de participación
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA2
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Italy
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del ultimo participante
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 36
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 18
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state1
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 2
    F.4.2.2In the whole clinical trial 54
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-08-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA